57,596 Shares in ICU Medical, Inc. $ICUI Bought by Legal & General Group Plc

Legal & General Group Plc purchased a new stake in ICU Medical, Inc. (NASDAQ:ICUI) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 57,596 shares of the medical instruments supplier’s stock, valued at approximately $8,444,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of ICUI. BlackRock Inc. acquired a new position in ICU Medical during the second quarter worth $550,250,000. Vanguard Group Inc. increased its position in shares of ICU Medical by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier’s stock worth $387,313,000 after acquiring an additional 89,755 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of ICU Medical by 3.9% during the first quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier’s stock worth $345,607,000 after acquiring an additional 99,256 shares in the last quarter. Millennium Management LLC raised its holdings in shares of ICU Medical by 173.4% in the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock worth $130,638,000 after acquiring an additional 690,694 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in ICU Medical by 6.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier’s stock valued at $127,053,000 after acquiring an additional 63,026 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

ICU Medical Stock Performance

ICUI stock opened at $170.81 on Wednesday. The firm has a market cap of $4.27 billion, a PE ratio of 144.75, a P/E/G ratio of 2.19 and a beta of 0.75. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56. The business has a 50 day moving average of $166.08 and a 200-day moving average of $144.35. ICU Medical, Inc. has a 12-month low of $112.50 and a 12-month high of $192.85.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.46. The company had revenue of $547.88 million during the quarter, compared to the consensus estimate of $533.44 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.ICU Medical’s revenue was up .5% on a year-over-year basis. During the same period last year, the business posted $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, sell-side analysts expect that ICU Medical, Inc. will post 7.19 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Zacks Research downgraded ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. BTIG Research increased their price objective on ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Weiss Ratings upgraded ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Piper Sandler lifted their target price on ICU Medical from $163.00 to $195.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Jefferies Financial Group upgraded ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $192.80.

Insiders Place Their Bets

In other news, VP Daniel Woolson sold 5,417 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $181.33, for a total transaction of $982,264.61. Following the completion of the sale, the vice president directly owned 17,062 shares of the company’s stock, valued at $3,093,852.46. This trade represents a 24.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ben Sousa sold 2,250 shares of ICU Medical stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $178.32, for a total value of $401,220.00. Following the sale, the insider owned 3,076 shares in the company, valued at $548,512.32. The trade was a 42.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 16,974 shares of company stock worth $3,085,844 over the last 90 days. Company insiders own 2.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.